Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2000 May 24

PMID 10823584

Citations 38

Authors

C Hesse

H Larsson

P Fredman

L Minthon

N Andreasen

P Davidsson

K Blennow

Affiliations

Soon will be listed here.

Abstract

Apolipoprotein E (apoE) is a protein involved in transport of lipids and has been implicated to play an important role in regeneration after nerve injury. Determination of apoE in cerebrospinal fluid (CSF) thus have a potential interest when studying different forms of brain damage and as a marker of ongoing regenerative processes in the brain. However, previous studies on CSF-ApoE in Alzheimer's disease (AD) have given inconclusive results. Such inconsistent results might be related to confounding factors interfering with sample handling and/or analyses, which have not been fully elucidated. We therefore examined different potential confounding factors for analyses of apoE in CSF and also developed a new enzyme linked immunosorbent assay (ELISA). The hydrophobic character of ApoE resulted in adsorption to different types of test tubes commonly used for collection of CSF at lumbar puncture, resulting in falsely low levels. This makes CSF handling critical, especially if samples are taken in different types of tubes, or is transferred to new tubes. Taking this confounding factors in consideration and analysing patient and control CSF handled in the same way and using the new ELISA, we could confirm our previous finding of reduced levels of ApoE in AD, (3.4 +/- 1.3 mg/l) compared with controls (4.5 +/- 2.7 mg/l) (p = 0.045). Both in the AD and in the control group, higher levels of CSF-ApoE was found in individuals possessing the ApoE4 alleles. Our results support that CSF-ApoE is reduced in AD, and that handling of CSF is a critical factor, which may explain the discrepant results from previous studies. Differences in the amount of patients and controls possessing the ApoE4 allele included might also increase the variance between different studies.

Citing Articles

Impaired Cerebrospinal Fluid Lipoprotein-Mediated Cholesterol Delivery to Neurons in Alzheimer's Disease.

Borras C, Canyelles M, Santos D, Rotllan N, Nunez E, Vazquez J Res Sq. 2025; .

PMID: 39764088 PMC: 11703344. DOI: 10.21203/rs.3.rs-5682870/v1.

Metrologically Traceable Quantification of 3 Apolipoprotein E Isoforms in Cerebrospinal Fluid.

Huynh H, Kuch K, Orquillas A, Forrest K, Barahona-Carrillo L, Keene D Clin Chem. 2023; 69(7):734-745.

PMID: 37279935 PMC: 10320014. DOI: 10.1093/clinchem/hvad056.

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.

Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando S Alzheimers Res Ther. 2022; 14(1):115.

PMID: 36002891 PMC: 9400269. DOI: 10.1186/s13195-022-01058-9.

Serum Levels of α-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function.

Kundu P, Zimmerman B, Quinn J, Kaye J, Mattek N, Westaway S J Alzheimers Dis. 2022; 86(3):1471-1481.

PMID: 35213382 PMC: 9108571. DOI: 10.3233/JAD-215719.

Fatty Acid Binding Protein 3 (FABP3) and Apolipoprotein E4 (ApoE4) as Lipid Metabolism-Related Biomarkers of Alzheimer's Disease.

Dulewicz M, Kulczynska-Przybik A, Slowik A, Borawska R, Mroczko B J Clin Med. 2021; 10(14).

PMID: 34300173 PMC: 8303862. DOI: 10.3390/jcm10143009.

References

Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B . Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun. 1993; 192(2):359-65. DOI: 10.1006/bbrc.1993.1423. View

Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B . Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett. 1997; 229(2):85-8. DOI: 10.1016/s0304-3940(97)00429-1. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Strittmatter W, Weisgraber K, Huang D, Dong L, Salvesen G, Pericak-Vance M . Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(17):8098-102. PMC: 47295. DOI: 10.1073/pnas.90.17.8098. View

Blennow K, Hesse C, Fredman P . Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 1994; 5(18):2534-6. DOI: 10.1097/00001756-199412000-00032. View

Bellosta S, Nathan B, Orth M, Dong L, Mahley R, Pitas R . Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem. 1995; 270(45):27063-71. DOI: 10.1074/jbc.270.45.27063. View

Pirttila T, Koivisto K, Mehta P, Reinikainen K, Kim K, Kilkku O . Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett. 1998; 249(1):21-4. DOI: 10.1016/s0304-3940(98)00381-4. View

Carlsson J, Armstrong V, Reiber H, FELGENHAUER K, Seidel D . Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta. 1991; 196(2-3):167-76. DOI: 10.1016/0009-8981(91)90070-s. View

Swanson L, SIMMONS D, Hofmann S, Goldstein J, Brown M . Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc Natl Acad Sci U S A. 1988; 85(24):9821-5. PMC: 282873. DOI: 10.1073/pnas.85.24.9821. View

10.

Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G . Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci. 1997; 145(1):33-9. DOI: 10.1016/s0022-510x(96)00234-1. View

11.

Boyles J, Pitas R, Wilson E, Mahley R, Taylor J . Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985; 76(4):1501-13. PMC: 424114. DOI: 10.1172/JCI112130. View

12.

Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K . Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett. 1997; 231(3):175-8. DOI: 10.1016/s0304-3940(97)00558-2. View

13.

Poirier J . Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994; 17(12):525-30. DOI: 10.1016/0166-2236(94)90156-2. View

14.

Leary J, Brigati D, Ward D . Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots. Proc Natl Acad Sci U S A. 1983; 80(13):4045-9. PMC: 394197. DOI: 10.1073/pnas.80.13.4045. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Roses A . Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 1996; 47:387-400. DOI: 10.1146/annurev.med.47.1.387. View

17.

Mahley R . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240(4852):622-30. DOI: 10.1126/science.3283935. View

18.

Roheim P, Carey M, Forte T, Vega G . Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A. 1979; 76(9):4646-9. PMC: 411636. DOI: 10.1073/pnas.76.9.4646. View

19.

Hogasen K, Mollnes T, Tschopp J, HARBOE M . Quantitation of vitronectin and clusterin. Pitfalls and solutions in enzyme immunoassays for adhesive proteins. J Immunol Methods. 1993; 160(1):107-15. DOI: 10.1016/0022-1759(93)90014-x. View

20.

Hahne S, Nordstedt C, Ahlin A, Nyback H . Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett. 1997; 224(2):99-102. DOI: 10.1016/s0304-3940(97)13477-2. View